Taking Aim at an Ideal Therapeutic Target in RRMM

Taking Aim at an Ideal Therapeutic Target in Relapsed/Refractory Multiple Myeloma
Taking Aim at an Ideal Therapeutic Target in Relapsed/Refractory Multiple Myeloma
CME, CPE, CE
Sarah A. Holstein, MD, PhD – Chair; Muhamed Baljevic, MD; Natalie S. Callander, MD
Release Date: August 27, 2020
Expiration Date: August 27, 2021

Awareness and knowledge of B-cell maturation antigen (BCMA) as a therapeutic target remains limited among clinicians who provide care for patients with relapsed/refractory multiple myeloma (MM). However, the number of clinical trials evaluating these therapies is rapidly increasing; and a few have even received breakthrough therapy status. In this activity, three experts provide a better understanding of BCMA as a target, along with an improved knowledge of emerging efficacy and safety data that may soon inform the use of these promising strategies in clinical practice.

This activity was previously presented between August 10 and 17, 2020 as a live webinar. Please note: If you participated in one of the live webinars, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Provided by
University of Nebraska Medical Center and MediCom Worldwide, Inc.
This activity is supported by an educational grant from GlaxoSmithKline.

Begin, Earn CreditView Only, No Credit